Success Metrics

Completion Rate

0%(0/1)

Active Trials

1(33%)

Terminated

1(33%)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Enrolling by invitation1

Active, not recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

enrolling_by_invitation133%

active_not_recruiting133%

terminated133%

Recent Activity

1 active trials

Showing 3 of 3

enrolling_by_invitationphase_1

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

NCT06603987

active_not_recruitingphase_2

A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

NCT05601232

terminatedphase_1

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

NCT00927147

Clinical Trials (3)

Showing 3 of 3 trials

NCT06603987Phase 1

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Enrolling By Invitation

NCT05601232Phase 2

A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

Active Not Recruiting

NCT00927147Phase 1

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type: RADIATION
Total Trials: 3